GlycoNex Inc. was founded in 2001, in alliance with The Biomembrane Institute (TBI) from Washington University and Dr. Sen-Itiroh Hakomori, a member of the National Academy of Sciences (USA). GlycoNex was the first pharmaceutical company in Taiwan to combine cancer-related glycan identification with human monoclonal antibody development. GlycoNex Inc. possesses a complete and detailed technological platform for anti-glycan antibody development, including multiple acquired licensed patents. Our pipeline consists of new drug development in parallel with biosimilars. Our new drugs were selected and developed through a detailed antigen/antibody characterization and cell line development. In 2009, we licensed GNX8 to Otsuka Pharmaceutical Co., Ltd. In 2019, our first-in-class new drug GNX102 received FDA IND approval. In 2020, we initiated our Clinical Trial Phase I dose-escalation study for GNX102 and received TFDA IND approval. In parallel, our biosimilar products Denosumab and Aflibercept have completed different volumes of pilot studies and data ready for review. We aim to look for opportunities of out-licensing our products or co-develop in cooperation.